



PEOPLE

DNA Sciences (Fremont, CA) has announced the appointment of **Christopher Burrow** as director of medicine. Dr. Burrow was previously an assistant professor of medicine at The Mount Sinai School of Medicine, as well as an associate attending in nephrology at The Mount Sinai Hospital in New York. The company also announced that **Gregory Went** has resigned as chief operating officer (COO) and director to pursue other interests.

Fritz Casselman has been appointed to the newly created position of chief business officer and senior vice president at ARIAD Pharmaceuticals (Cambridge, MA). He is currently senior vice president, strategy and corporate development at Avant Immunotherapeutics, and was previously director of worldwide business development at SmithKline Beecham.

HTS Biosystems (Hopkinton, MA) has announced that **Joseph A. Ciffolillo** and **Larry M. Gold** have joined its board of directors. Mr. Ciffolillo is a director of Boston Scientific Corp. Before his retirement Mr. Ciffolillo was executive vice president and COO of Boston Scientific. Dr. Gold is chief executive officer (CEO) and chairman of SomaLogic, a proteomics company using aptamer technologies.

Lawrence K. Cohen has been named CEO of Zyomyx (Hayward, CA), succeeding **Yasunori Kaneko**. Dr. Cohen joined Zyomyx in April 1999. Dr. Kaneko will continue in his position as chairman of the board of directors. The company has also announced the appointment of **Garrett J. Roper** to the position of senior vice president, chief financial officer (CFO). Mr. Roper was previously a co-founder and senior vice president, CFO of OnCare Inc.

Bristol-Myers Squibb (New York) has named **Peter R. Dolan** as its next CEO, succeeding **Charles Heimbold**, who will retire later this year. Mr. Dolan, who was appointed president and elected to the board in January 2000, will formally assume the responsibilities of CEO on May 1. Mr. Heimbold will remain chairman of the board until his retirement.

Pharmagenesis (Palo Alto, CA) has named **Nicolas Druz** as chairman and CEO. Mr. Druz also serves as chairman and CEO of Orchid, a Luxembourg-based financial holding company. Pharmagenesis also named **François Guinot** as president. Mr. Guinot is a board member and managing director of BioMerieux-Pierre Fabre, and a

director of Transgene, a French biopharmaceutical company.

Judith Kurland, former New England Regional Director of the US Department of Health and Human Services, has been elected to the board of directors of Matritech (Newton, MA).

Exelixis (S. San Francisco, CA) has announced the following staff additions: **Peter Lamb** as senior director of molecular pharmacology and structural biology, **Kirk McMillan** as director of new lead discovery, **John Nuss** as senior director of chemistry, and **Yifan Zhai** as director of pharmacology. Dr. Lamb most recently served as director of transcription research at Ligand Pharmaceuticals; Dr. McMillan joins from Pharmacopeia, where he was assistant director of drug discovery; Dr. Nuss most recently served as director of organic and medicinal chemistry for Chiron; and Dr. Zhai joins the company from Bayer, where he was senior research scientist, department of cancer research, pharmaceutical division.

James A. Myer has joined the board of directors of Structural Bioinformatics (San Diego, CA). Dr. Myer founded and has served as president and chairman of Photon Research Associates since 1976.

Applied Molecular Evolution (San Diego, CA) has named **John F. Richards** to its board of directors. Mr. Richards is a general partner of Crabtree Ventures, a venture capital life science fund. Additionally, **John G. Morris** of HarbourVest Partners has left the AME board to focus on his portfolio of private company investments.

Bradley J. Thatcher has been appointed vice president, proteomics discovery for SYN X Pharma (Toronto, ON, Canada). Before joining SYN X, Dr. Thatcher was a senior field scientist specializing in proteomics and director of special projects for CIPHERgen Biosystems.

Keryx Biopharmaceuticals (Boston, MA) has announced the appointment of **J. Wilson Totten** and **Malcolm I. Hoenlein** to the company's board of directors. Dr. Totten has held the position of group R&D director at Shire Pharmaceuticals since 1998. Mr. Hoenlein is the executive vice chairman of the Conference of Presidents of Major American Jewish Organizations, and serves on the boards of several public companies and organizations, including Rothschild Bank, Bank Leumi USA, the Council on Foreign Affairs, and the America-Israel Chamber of Commerce.

